Hemophilia B is an X-chromosomal recessive disease due to deficiency of coagulation factor IX. Three monoclonal antibodies against factor IX were prepared and used to develop immunoradiometric assays (IRMAs) of factor TX antigen (IX-Ag). TX-Ag was measured in 65 normal individuals with bne IRMA based on polyclonal anti-IX antibodies and two IRMAs based on three monoclonal anti-IX antibodies. One of the monoclonal antibodies differed in specificity since it neutralized <50% of the dotting activity of factor IX (IX-C), whereas the other two monoclonal antibodies neutralized 80-95%. When the former antibody was used as the solid phase in IRMA, two groups of normal individuals were distinguished: group A with measurable TX-Ag, and group B without demonstrable TX-Ag. There were no differences between the groups either in IX-C or in IX-Ag measured with polyclonal antibodies. A subgroup comprising only women could be distinguished in group A, in whom intermediate IX-Ag concentrations were found. Family studies showed the group B variant of normal factor TX to be transmitted according to the pattern of X-linked recessive inheritance. The allelic frequency of group A was 0.66, and that of group B was 0.34.
Hemophilia B is due to a deficiency of factor IX, a coagulation protein involved in the intrinsic phase of blood coagulation. The disease has a recessive X-linked mode of inheritance and can be classified as severe, moderate, or mild, according to the biological activity of factor IX (IX-C) in plasma (1, 2). Molecular variants of factor IX in hemophilia B were detected after it had become possible to measure factor IX antigen (IX-Ag) by using different immunological assays based on polyclonal allogenous or xenogenous antibodies (3) (4) (5) (6) . Antigen concentrations varied widely from family to family, partly owing to differences in the specificity of the various antibodies used. The structural basis of these inherited defects has not been established, although gross gene deletions have been shown to exist in some of the hemophilia B patients (7) .
The structure of normal human factor IX has been determined by isolation and characterization of a cDNA, and was found to be a polypeptide chain composed of 416 amino acids (8) . The polypeptide chain is activated by cleavage of two internal peptide bonds and transformed to a serine protease composed of a light and heavy chain (9, 10) , the active site being located in the heavy chain (8) . Recently a restriction fragment length polymorphism has been observed in the factor IX gene by means of cDNA probes derived from mRNA (11) (12) (13) .
In this work, molecular variants of the normal human factor IX are demonstrated by measuring IX-Ag in normal individuals with immunoradiometric assays (IRMAs) based on three monoclonal antibodies and one polyclonal antibody. When one of the monoclonal antibodies was used as solid phase in the assays 10 of the 29 men (34%) investigated and 5 of the 36 women (14%) had no detectable IX-Ag. A subgroup comprising at least 6 females with intermediate concentrations of IX-Ag was distinguished among the remaining 31 females. However, no difference in IX-C was found, despite the differences in IX-Ag. Analyses of normal families showed the variant with undetectable IX-Ag to be transmitted according to the pattern of X-linked recessive inheritance.
MATERIALS AND METHODS
Subjects. Blood was collected in 3.8% sodium citrate solution (9:1, vol/vol) from 65 normal individuals (medical students and laboratory staff; 29 men, 36 women), their mean age being 34 years (range 18-59). In addition, 3 propositi were selected for family studies, which led to the addition of 27 subjects to the study. Platelet-poor plasma was prepared by centrifugation at 2000 x g for 20 min. The plasma samples were stored at -800C until analyzed. Plasma was also obtained from a patient with severe hemophilia B, who had been defined in earlier studies as cross-reacting material negative (CRM-) (6) .
Immunization, Cell Fusion, and Growth of Clones. Factor IX was purified as described (14, 15) , and was activated by purified human factor XIa. Both factor IX and factor IXa were kindly supplied by W. Kisiel (Department of Biochemistry, University of Washington, Seattle). Sixty micrograms of purified factor IX was emulsified in complete Freund's adjuvant (Difco) and injected subcutaneously into 3-month-old BALB/c mice. After 25 days the mice received subcutaneous booster injections of 60 pug of protein without adjuvant. A final intravenous injection of 60 pug was given 9-10 weeks after priming. Four days later the spleen cells of the mice were harvested, fused with Sp 2/0-Ag 14 mouse myeloma cells, and seeded in 96-well culture plates as described (16) . Culture supernatants were screened for specific antibodies 10-20 days after fusion. Selected positive hybridomas were cloned four times by using the limiting dilution technique (17) and preserved in liquid nitrogen or grown as ascites tumors in BALB/c mice.
Screening of Antibodies Against Factor TX. Hybridoma supernatants were screened for specific antibodies by using a solid-phase radioimmunoassay with purified factor IX coated to the wells of polyvinylchloride microtiter plates and radiolabeled staphylococcal protein A as developing reagent, essentially as described by Buchanan et al. (18) .
Abbreviations: IX-C, factor IX coagulant activity; IX-Ag, factor IX antigen; IRMA, immunoradiometric assay.
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Purification and Radiolabeling of the Monoclonal Antibodies. The total immunoglobulin G (IgG) was prepared from ascites fluid by ammonium sulfate precipitation, overnight dialysis, and DEAE-Sephacel ion-exchange chromatography (16) . The IgG was further purified by affinity chromatography on factor IX-Sepharose 4B, using a batch procedure (19) . The eluted IgG was assayed and stored in Tris-buffered saline, pH 7.5, at 4TC in the presence of 0. 1% (15 mM) sodium azide. The purified antibodies were labeled with 125I by the lactoperoxidase method (20) . Specific activities obtained were =1.0 MBq/jug of IgG.
Neutralization Test. The anti-IX-C effect of the monoclonal antibodies was tested as described (19) . The IgG preparations in various dilutions (60-1000 ,g/ml) were incubated for 60 min at 37TC with 5 units/ml purified factor IX (-35 gg/ml) or factor IXa (z0.9,ug/ml), and the residual IX-C was measured (see below). A reference curve was constructed of serial dilutions of purified factor IX, incubated with 3 kug/ml of an unrelated monoclonal antibody (R2) against factor VIIIrelated antigen (21) .
Monoclonal Anti-IX-Sepharose. Purified monoclonal antibodies 9.1 and 9.9 (see below) were coupled to cyanogen bromide-activated Sepharose 4B (5 mg of IgG per ml of gel) as recommended by the manufacturer (Pharmacia). Pooled plasma (4 ml) from two normal individuals was assayed for various clotting factors (see below) both before and after passage through the column. The results were compared with those obtained when purified normal human IgG was coupled to Sepharose 4B by using the same procedure.
Analyses. The protein content of the IgG preparations was measured with Bradford's method (22) , and the IgG content was determined immunochemically by using Laurell's rocket technique (23) and commercial antisera (Sigma). The IgG samples were carbamoylated before electrophoresis. NaDodSO4/polyacrylamide gel electrophoresis of the purified monoclonal antibodies was performed in 8.5% polyacrylamide gels both with and without a reducing agent (24) . The IgG subclasses and the light chains of the monoclonal antibodies were determined by using the same technique as in the screening procedure, specific antiserum to mouse IgG1, IgG2a, IgG2b, IgG3, K chain, or X chain (Miles) being used as second layer.
Polyclonal Antibodies Against Factor IX. Polyclonal antibodies were isolkted from a hemophilia B patient who had an inhibitor titer of 50 Malmo units/ml (corresponding to 150 Bethesda units/ml). The IgG was prepared and radiolabeled as described (25) .
TX-C Assay. IX-C was measured in all subjects by using a one-stage recalcification assay as described by Nilsson (26) . Citrated pooled plasma from 20 normal individuals was used as reference plasma. The activity was expressed as units/dl. One unit was defined as the activity present in 1 ml of normal plasma. The normal range was 60-140 units/dl.
Other Coagulation Assays. Factor XI, XII, fibrinogen, factor VIII coagulant activity (VIII-C), and factor VIIIrelated antigen (VIII-R-Ag) were assayed as described (26, 27) . Antithrombin III and a2-antiplasmin were determined amidolytically, using S-2238 and S-2251 (KabiVitrum, Stockholm, Sweden), respectively. TX-Ag Assays. IX-Ag was determined in all subjects with three different two-site solid-phase IRMAs. IRMA I was based on the polyclonal human hemophilic antibody, which was used both for the immobilization of IX-Ag and (radiolabeled) for the detection of bound IX-Ag (25) . The normal range was 60-160 units/dl. In IRMA II and IRMA III, the monoclonal antibody 9.9 (see below) was used as the solid phase, and the radiolabeled monoclonal antibodies 9.1 (IRMA II) or for both IRMAs. The sensitivity limit of these methods was 0.10 unit/dl. Coefficients of variation within assay at different plasma dilutions were 0lo and between assays they were =15%.
RESULTS
Monoclonal Antibodies Against Factor IX. Ninety-six wells showed hybridoma growths and initially there were 12 positive cultures when the supernatants were tested by means of the screening assay. Three of these (9.1, 9.5, and 9.9) were recloned four times and grown in BALB/c mice for ascites production. The monoclonal antibodies were prepared from ascites fluid, and the purity of the fractions after affinity chromatography was confirmed on NaDodSO4/polyacrylamide gels, which showed only one band in the IgG region, two bands when a reducing agent was present. Protein content in the pooled fractions was 0.5-2.0 mg/ml, and all three monoclonal antibodies were found to belong to the subclass IgG1 with K light chains.
Neutralization Test. The residual IX-C after incubation of purified factor IX or factor IXa with each of the three monoclonal antibodies and human polyclonal anti-IX antibodies is shown in Fig. 1 . The 9.5 antibody inhibited both factor IX and IXa most efficiently, even more than the polyclonal antibodies. The 9.9 antibody showed weaker Proc. Natl. Acad Sci. USA 82 (1985) Proc. Natl. Acad. Sci. USA 82 (1985) 3841 inhibitory activity than either 9.1 or 9.5, never exceeding 50%o inhibition, even at a concentration of 1000 gg of IgG per ml.
Monoclonal Anti-IX-Sepharose. Coupled to Sepharose 4B, antibodies 9.1 and 9.9 removed -95% of IX-C in plasma passed through the columns. No such effect was found with normal human IgG similarly coupled to Sepharose. Other coagulation factors investigated in the passed plasma were unaffected (not shown).
IX-C. Normal IX-C concentrations were obtained in all 65 normal individuals and in all 27 members in the three families investigated (Table 1) .
TX-Ag. When IRMA I, in which the same polyclonal human antibodies were used for coating and detection, was used, all normal individuals and family members investigated had IX-Ag concentrations within the normal range. In IRMAs II and III, the monoclonal antibody 9.9, which neutralized <50%o of IX-C, was used for coating. For detecting bound IX-Ag, the radiolabeled monoclonal antibody 9.1 (TRMA II) or 9.5 (IRMA III) was used. Two distinct groups emerged when IX-Ag was measured with these two methods: group A, with measurable IX-Ag (19 men, 31 women), and group B, without measurable IX-Ag (<0.1 unit/dl) (10 men, 5 women). There was no difference in IX-C or IX-Ag (IRMA I) between the groups according to two-way analysis of variance [between-groups F(1/61) = 0.07 and 0.22; between-sex F(1/61) = 0.01 and 0.50; interaction F (1/61) = 0.08 and 0.05, respectively]. Linear regression analysis showed a significant correlation between the results obtained by IRMAs II and III (r = 0.89). When plasma from a patient with severe hemophilia B was tested by using the different IRMAs, no binding of radioactivity was found (Fig. 2) . Fig. 2 also shows the differences in bound radioactivity obtained when pooled plasma from 6 men belonging to group A was used instead of the pooled plasma from 20 normal individuals described earlier. Fig. 3 demonstrates the distribution ofIX-Ag in group A when measured with IRMAs TT and III, using the reference curve based on pooled group A plasma. As shown in Fig. 3 Family Studies. To evaluate the hereditary pattern of the observed variants of factor IX, three families were investigated. In family I (Fig. 4a) none had IX-Ag measurable by using the monoclonal IRMAs (i.e., all tested belonged to group B). In family 2 (Fig. 4b) NaDodSO4/polyacrylamide gels. They may be regarded as being specific for IX-Ag since they bind to purified human factor TX and to factor TX present in normal pooled plasma but do not react with plasma from a patient with severe hemophilia B. When immobilized on Sepharose 4B, the antibodies remove factor TX-C selectively from normal plasma. Antibodies 9.1 and 9.5 had similar characteristics and neutralized 80-95% of TX-C, whereas the third monoclonal antibody (9.9) had distinctly different properties and neutralized <50% of TX-C. Presumably antibody 9.9 is directed against an immunoreactive site remote from the part of the molecule associated with the clotting activity, and structural differences in this part of the molecule are less prone to affect the clotting activity of the protein.
In Pedigree analysis clearly showed group B variant of factor TX to be inherited in the X-linked recessive way. Family 1 (Fig.  4a) obviously has only one of the alleles for factor TX. Families 2 and 3 ( Fig. 4 b and c) Earlier studies with monoclonal antibodies against factor IX did not reveal polymorphism in the normal population (29) (30) (31) (32) (33) (34) (35) . The monoclonal antibody used in the study by Thompson (30) was directed against structures on the heavy chain, where the coagulation active site is situated. Two recent studies of DNA in normal individuals have revealed a restriction fragment length polymorphism of the factor IX gene (11, 13) . It is noteworthy that the allelic frequencies found with the Taq I restriction enzyme in the two studies (11, 13) , 0.29/0.71 and 0.35/0.65, respectively, are of magnitude comparable to those found in our study for men belonging to group B or A (0.34/0.66). However, the two normal factor IX proteins demonstrated in our study cannot be the products of the two alleles shown by the Taq I restriction enzyme since the Taq I polymorphic site is within an intron of the gene (12, 36) . Differences have been found in the nucleotide sequence of the human factor IX mRNA at position 609 in two studies (36, 37) . Such a difference would alter the amino acid sequence in the activation peptide. However, this cannot be the polymorphic site in our study since antibody 9.9 reacts with both factor IX and factor IXa.
An inherited variation in protein structure without the function being affected is recognized in several other plasma proteins, such as haptoglobin, transferrin, immunoglobulins, albumin, and a1-antitrypsin (38) (39) (40) (41) (42) (43) . The structural basis for the allelism of factor IX-whether it is a substitution, deletion, or insertion in the molecule-has yet to be established.
Our conclusion is that there exist at least two genetically determined molecular variants of normal human factor IX, and we propose that they be designated IX-1 (group A) and IX-2 (group B). Studies with other monoclonal antibodies together with further knowledge of the factor IX gene may reveal a yet more complex polymorphism. The polymorphism may also prove useful as a marker of the X chromosome in carrier detection.
